jevtana- cabazitaxel kit
sanofi-aventis u.s. llc - cabazitaxel (unii: 51f690397j) (cabazitaxel - unii:51f690397j) - cabazitaxel 60 mg in 1.5 ml - jevtana® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. jevtana is contraindicated in patients with: - neutrophil counts of ≤1,500/mm3 [see warnings and precautions (5.1)] - history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80 [see warnings and precautions (5.3)] - severe hepatic impairment (total bilirubin >3 × uln) [see warnings and precautions (5.8)] risk summary the safety and efficacy of jevtana have not been established in females. there are no human data on the use of jevtana in pregnant women to inform the drug-associated risk. in animal reproduction studies, intravenous administration of cabazitaxel in pregnant rats during organogenesis caused embryonic and fetal death at doses lower than the maximum recommended human dose [see data] . data animal data in an early embryonic developmental toxicity stu
cabazitaxel teva 10 mg/ml inf. sol. (conc.) i.v. vial
teva b.v. - cabazitaxel ethyl acetate 11,05 mg/ml - eq. cabazitaxel 10 mg/ml - concentrate for solution for infusion - 10 mg/ml - cabazitaxel ethylacetate 11.05 mg/ml - cabazitaxel
cabazitaxel mylan 60 mg i.v. vial
viatris gx bv-srl - cabazitaxel 40 mg/ml - concentrate and diluent for solution for infusion - 60 mg - cabazitaxel 40 mg/ml - cabazitaxel
cabazitaxel ever pharma 10 mg/ml inf. sol. (conc.) i.v. vial
ever valinject gmbh - cabazitaxel ethyl acetate 45 mg - concentrate for solution for infusion - 10 mg/ml - cabazitaxel 10 mg/ml - cabazitaxel
cabazitaxel ever pharma 10 mg/ml inf. sol. (conc.) i.v. vial
ever valinject gmbh - cabazitaxel ethyl acetate 45 mg - concentrate for solution for infusion - 10 mg/ml - cabazitaxel 10 mg/ml - cabazitaxel
cabazitaxel ever pharma 10 mg/ml inf. sol. (conc.) i.v. vial
ever valinject gmbh - cabazitaxel ethyl acetate 45 mg - concentrate for solution for infusion - 10 mg/ml - cabazitaxel 10 mg/ml - cabazitaxel
cabazitaxel viatris 20 mg/ml inf. sol. (conc.) i.v. vial
viatris gx bv-srl - cabazitaxel 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - cabazitaxel 20 mg/ml - cabazitaxel
cabazitaxel ever pharma 10 mgml
pharmalogic ltd - cabazitaxel - concentrate for solution for infusion - cabazitaxel 10 mg / 1 ml - cabazitaxel - cabazitaxel is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel- containing treatment regimen.
cabazitaxel fresenius kabi 20 mg/ml concentrate for solution for infusion
fresenius kabi italia s.r.l via camagre 41, 37063 isola della scala (vr) , italy - concentrate for solution for infusion - cabazitaxel 20 mg/ml - antineoplastic agents
jevtana cabazitaxel 60 mg/1.5 ml concentrated injection vial
sanofi-aventis australia pty ltd - cabazitaxel acetone solvate, quantity: 64.17 mg - diluent, not applicable - excipient ingredients: water for injections; ethanol - jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.